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Aspergillus, Candida and Cryptococcus spp. infections who are refractory to or 
intolerant of conventional amphotericin B. The model was built from a hospital 
perspective, and included drug acquisition costs and costs for treating drug-
related adverse events (AEs) within a hospital stay. The treatment duration of L-
AmB and ABLC and rates of AEs for these two treatments were mainly obtained 
from a retrospective study of these two drugs in the target population using 
Cerner’s Health Facts data. Treatment costs of AEs were obtained from publicly 
available sources. The budget impact (2011USD) was evaluated by changing the 
market share of L-AmB and ABLC from 50/50% to 80/20%. One-way sensitivity 
analyses were conducted by varying drug cost, treatment duration, and rates and 
costs of AEs. RESULTS: The per-patient costs associated with L-AmB and ABLC 
during one hospital stay were $14,563 and $16,748, respectively. Cost of AEs 
attributed to 68.7% of the costs for L-AmB and 85.4% for ABLC. In a hypothetical 
hospital with 100 annual admissions of patients using one of these two drugs for 
fungal infections, changing the market shares from 50/50% for L-AmB and ABLC, 
respectively, to 80/20% yielded a cost saving of $65,561. Sensitivity analyses 
indicated that the results were robust to changes in input parameter values. 
CONCLUSIONS: This study suggests that hospitals can realize cost savings by 
substituting ABLC with L-AmB in the treatment of invasive fungal infections. The 
cost savings are driven by the lower rates of AEs associated with L-AmB 
compared to ABLC.  
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OBJECTIVES: Skin and soft tissue infections (SSTI) are common and complicated 
SSTIs (cSSTI) is the more extreme end of this clinical spectrum. The aim of this 
analysis is to estimate the budget impact of Linezolid in the treatment of cSSTI 
in Colombia. METHODS: A model was built with a horizon of three years.  
The comparators were: Linezolid (600mg IV/twice day) switch (600 orally/twice 
day) compared with Vancomycin (1 g IV/twice day), Daptomycin (4 mg IV/kg/day) 
and Tigecycline (100 mg IV followed by 50 mg twice day). The analysis used the 
third payer perspective including only direct medical costs. Costs were taken 
from health care institutions. Resource use and costs (drug acquisition, inpatient 
stay, health care professional visits, and lab tests). Costs were expressed in 2012 
$ US. The calculation of patients likely to be treatment was estimate using data 
published in the literature on the incidence of patients hospitalized for SSTI  
and the percentage of methicillin-resistant Staphylococcus aureus (MRSA)  
in cSSTI, this data were applied the Colombian population projected by the 
national administrative department of statistics for 2012. Univariate sensitivity 
analyses were performed. RESULTS: With an incidence of 0.16 hospitalizations 
for SSTI per 10,000 hospital visits per year, and considering the market share 
growth of Linezolid from 15% to 35% over 3 years, the model showed a reduction 
of approximately $ US 15,609,105.97 in total costs for disease treatment . If  
the market share of Linezolid would be increased 1% there could be savings for  
$ US 460,428.26 (first year). CONCLUSIONS: Linezolid is a favorable alternative  
for the treatment of cSSTI, considering the lower cost of treatment per patient ($ 
US 8,226.25) per year compared with other available antimicrobial therapies, 
which would mean relevant savings in the context of health system in this 
country.  
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OBJECTIVES: Complicated skin and soft tissue infections (cSSTIs) are ones of the 
largest reasons for increased hospitalization; these are often attributed to 
Staphylococcus aureus and Streptococcus pyogenes which represent a major 
health burden that soar health care costs. The aim of this analysis is to estimate 
the impact on the budget of linezolid in the treatment of cSSTI in the Chilean 
private scenario. METHODS: A budgetary model was built within a time horizon 
of three years. Antimicrobial therapies used were: linezolid (1200 mg/day), 
vancomycin (2 mg/day), daptomycin (350 mg/day) and tigecycline (100 mg/day). 
The private payer’s perspective was used considering direct medical costs only. 
Resource use and costs of acquisition drug, inpatient stay, health care 
professional visits, and lab test, were collected from health care institutions from 
the private sector (Previsional Health Institutions – ISAPRE). Incidence of 
hospitalization due to cSSTI and percentage of methicillin-resistant 
Staphylococcus aureus (MRSA) in cSSTI were taken from literature and applied to 
the Chilean estimated population. Costs are in 2012 USD. RESULTS: Assuming a 
market share growth from 15% to 35% over three years with Linezolid, and 
taking into account 0.164% incidence of hospitalized skin and skin structure 
infections and a percentage of MRSA in cSSTI of 58%. The model showed a 
reduction of approximately US$343.18 per patient in total costs for disease 
treatment (US$101,834,379.86 for all included population [n=296,735]) due to 
lower time in UCI and lower costs for outpatient treatment. CONCLUSIONS: 
Considering the savings generated in the total treatment (drugs and medical 
costs for inpatient and outpatient treatment) of cSSTI with linezolid compared 
with other available antimicrobial therapies, Linezolid is the treatment of choice 
by meaning savings in the context of Previsional Health Institutions (ISAPRE) in 
Chile.  
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OBJECTIVES: Skin and soft tissue infections (SSTI) is a common cause of 
morbidity, both in the community and within hospitals. Its treatment is limited 
to the increased likelihood of methicillin-resistant Staphylococcus Aureus (MRSA) 
which has been identified as the predominant cause of SSTI. In case of 
complicated SSTI (cSSTI) the probability of hospitalization raises generating 
higher health care costs. Therefore, the aim of this analysis was to estimate the 
budgetary impact of linezolid in the treatment of cSSTI from the Chilean public 
payer’s perspective. METHODS: A model was built within a three years 
timeframe to estimate the financial impact of different authorized therapies for 
cSSTI. Comparators were: linezolid (1200 mg/day), vancomycin (2 mg/day), 
daptomycin (350 mg/day) and tigecycline (100 mg/day). Only direct medical costs 
were considered. Resource use and costs (acquisition drug, inpatient stay, health 
care professional visits, and lab tests) were retrieved from Chilean health care 
institution databases (National Fund of Health – FONASA). Calculation of 
patients likely to be treatment was estimate using data published in the 
literature about the incidence of patients hospitalized SSTI and percentage of 
MRSA in cSSTI. Costs were expressed in 2012 US$ and univariate sensitivity 
analyses were performed. RESULTS: With an incidence of 0.164 hospitalizations 
for SSTI in the public sector per 10,000 hospital visits per year, and considering a 
market share growth of linezolid from 15% to 35% over three years, the model 
showed a reduction of approximately US$65,577.05 in overall costs for disease 
treatment (US$4 per patient); if the market share of linezolid would be increased 
1% there could be savings for US$608,207.8 (first year). CONCLUSIONS: Linezolid 
is a favorable therapy for the treatment of cSSTI, considering the lower cost of 
treatment per patient (US$3489) compared with other available antimicrobial 
therapies, which would mean relevant savings to the National Fund of Health 
(FONASA) in Chile.  
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OBJECTIVES: Pneumococcal disease is a public health concern worldwide. This 
study evaluates the budget impact of PCV 13 vaccination with free campaign for 
corporations, versus no vaccination for individuals with 60+ years of age. 
METHODS: A budget impact analysis was developed considering vaccination 
costs, wage and productivity loss from employee absence due to sickness or 
death. Clinical events were calculated using a Markov model with individual-
level simulation considering a cohort of 1.000.000 individuals of 60 years of age 
in a time horizon of 5 years, assuming a retirement age of 65. Vaccines 
effectiveness’ were extrapolated from infant results. Absence days due to health 
events were retrieved from national labor legislations. Average wage was 
retrieved from the Brazilian Institute for Geography and Statistics (IBGE) 2012 
data and productivity was estimated from the indicator ‘revenue generated by 
the employee’, from a market research developed by Exame magazine in 2012 
using IBGE and the Brazilian Central Bank data. The base case considered a large 
corporation in Brazil with approximately 4.000 eligible individuals. Values were 
expressed in 2012 US$. RESULTS: PCV13 with free campaign totaled US$61,40 per 
employee. Productivity loss due to sick leave and death per employee was 
respectively US$641,97 and US$712,61 for PCV13 and no vaccination. Considering 
all evaluated costs per employee and the number of eligible individuals, PCV13 
and no vaccination totaled US$2.813.483,66 and US$2.850.451,98 respectively, 
representing US$36.968,32 of total savings for PCV13 vaccination when compared 
to no vaccination. CONCLUSIONS: The PCV13 vaccination plus a free campaign 
initiative is estimated to save costs to the employee, when compared to no 
vaccination, mainly driven by productivity loss due to sick leave and death, 
which represented 115,52% of the total investment in a time horizon of 5 years 
for individuals of 60+ years of age.  
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OBJECTIVES: This study evaluates the budget impact of PCV 13 vaccination with 
free campaign for corporations, versus a hypothetical scenario where the 
corporation would pay campaign expenditures as proposed for PCV13 while 
vaccinating with PPV23. METHODS: A budget impact analysis was developed 
considering vaccination costs, campaign and associated health management 
costs, wage and productivity loss from employee absence due to sickness or 
death. Clinical events were calculated using a Markov model with individual-
